LTX-315 is an oncolytic peptide. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it is being studied in clinical trials and is not approved by the FDA.
Regulatory status
LTX-315 is investigational.
It has not been approved by the FDA for any use.
ClinicalTrials.gov lists 5 registered studies for it.
The evidence
One source on LTX-315, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.
See the OPTML ScoreEducational reference only. This page explains what has been published about LTX-315. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides